

Article

Prediagnosis Depression Rather Than Anxiety Symptoms Is Associated with Decreased Ovarian Cancer Survival: Findings from the Ovarian Cancer Follow-Up Study (OOPS)

Yi-Zi Li ^{1,2,3,†}, Xue Qin ^{4,†}, Fang-Hua Liu ^{1,2,3}, Wen-Xiao Chen ⁵, Yi-Fan Wei ^{1,2,3}, Na Wang ⁶, Shi Yan ^{1,2,3}, Ye Kang ⁷, Yu-Hong Zhao ^{1,2,3}, Song Gao ⁴, Ting-Ting Gong ^{4,*} and Qi-Jun Wu ^{1,2,3,4,8,*}

¹ Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang 110004, China

² Clinical Research Center, Shengjing Hospital of China Medical University, Shenyang 110004, China

³ Liaoning Key Laboratory of Precision Medical Research on Major Chronic Disease, Shengjing Hospital of China Medical University, Shenyang 110004, China

⁴ Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China

⁵ Department of Sports Medicine and Joint Surgery, The People's Hospital of Liaoning Province, Shenyang 110000, China

⁶ Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200433, China

⁷ Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110004, China

⁸ Key Laboratory of Reproductive and Genetic Medicine, National Health Commission, China Medical University, Shenyang 110004, China

* Correspondence: gongtt@sj-hospital.org (T.-T.G.); wuqj@sj-hospital.org (Q.-J.W.); Tel.: +86-24-96615-13652 (T.-T.G.); +86-24-96615-13652 (Q.-J.W.)

† These authors contributed equally to this work.

Citation: Li, Y.-Z.; Qin, X.; Liu, F.-H.; Chen, W.-X.; Wei, Y.-F.; Wang, N.; Yan, S.; Kang, Y.; Zhao, Y.-H.; Gao, S.; et al. Prediagnosis Depression Rather Than Anxiety Symptoms Is Associated with Decreased Ovarian Cancer Survival: Findings from the Ovarian Cancer Follow-Up Study (OOPS).

J. Clin. Med. **2022**, *11*, 7394.

<https://doi.org/10.3390/jcm11247394>

Academic Editor: Sergio Marchini

Received: 8 November 2022

Accepted: 10 December 2022

Published: 13 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Background: The relationship between prediagnosis depression, anxiety symptoms, and ovarian cancer (OC) survival is unknown. We aimed to explore these associations to provide further epidemiological evidence. Methods: We investigated the relationship between prediagnosis depression, anxiety symptoms, and OC survival in a prospective cohort study of newly diagnosed OC patients aged 18–79 years. Depression and anxiety symptoms were assessed using the Patient Health Questionnaire 9 and Generalized Anxiety Disorder 7 at diagnosis, respectively. Deaths were ascertained until 31 March 2021 via medical records and active follow-up. Multivariable-adjusted Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with prediagnosis depression and anxiety symptoms and all-cause mortality of OC. Results: We found 56 (9.4%) and 235 (39.3%) OC patients with depression and anxiety symptoms, respectively. During a median follow-up of 37.2 months (interquartile range 24.7–50.2 months), 130 deaths were confirmed. Compared with non-depression symptoms, patients with prediagnosis depressive symptoms showed a significantly increased risk of OC mortality (HR = 2.10, 95% CI: 1.20–3.70). Of note, the association was still robust when focusing on the OC patients with severe depressive symptoms (HR = 2.10, 95% CI: 1.07–4.12). However, we observed no association between prediagnosis anxiety symptoms of different severity and OC mortality. Interestingly, OC patients with combined moderate depression and anxiety symptoms had a significantly increased risk of OC mortality (HR = 3.23, 95% CI: 1.14–9.11) compared to those with no symptoms of depression and anxiety. Notably, Wilms's tumor 1 was significantly associated with depression and anxiety symptoms ($p < 0.05$). Conclusions: Prediagnosis depression increases the risk of OC mortality. Large multicenter studies are required to confirm this finding.

Keywords: anxiety; cohort; depression; ovarian cancer; survival

1. Introduction

Ovarian cancer (OC) is the deadliest gynecologic cancer and the fourth-leading cause of cancer-related death in women [1]. In 2020, an estimated 313,959 women were diagnosed with OC and 207,252 died from this condition worldwide [1]. Due to the lack of early and specific symptoms, more than 75% of OC cases are diagnosed at an advanced stage, with an age-standardized survival rate of five years below 25% [1,2]. Although it has been proven that cancer clinical characteristics and treatment are important determinants of OC prognosis, evidence of the influence of modifiable prediagnosis psychosocial factors is still limited.

During the last decade, depression and anxiety have been proposed as the most common psychosocial characteristics that could play an etiologic role in and bear a prognostic impact on cancers [3–5]. Depression and anxiety are prevalent and disabling mental disorders that frequently co-occur with health outcomes [6,7]. Recent evidence suggests that psychosocial mechanisms of depression and anxiety include the expression of stress hormones such as cortisol and catecholamines, respectively, from the deregulated hypothalamic–pituitary–adrenal axis and the sympathetic nervous system, which may promote growth and progression of OC via stress-mediated pathways [8]. Previous evidence has shown that OC patients present a range of psychological symptoms during stages of diagnosis, treatment, and survival, mainly with high levels of depression and anxiety [9]. A recent meta-analysis suggests that the prevalence of depression and anxiety in OC patients is considerably greater across the treatment spectrum than in the healthy female population [10]. Specifically, pretreatment, in-treatment, and posttreatment depression prevalence among OC patients was 25.34%, 22.99%, and 12.71%, respectively [11]. Furthermore, pretreatment, in-treatment, and posttreatment anxiety prevalence among OC patients was 19.12%, 26.23%, and 27.09%, respectively [11]. However, little is known about the relationship between depression and anxiety symptoms and mortality of OC. Recently, only two studies have evaluated the association between prediagnosis depression and anxiety and OC survival [12,13]. Clarke et al. [12] reported that a diagnosis of depression within the year prior to a cancer diagnosis, evaluated by the Elixhauser comorbidity score, was inversely associated with long-term survival based on a retrospective study of 642 high-grade serous OC patients. Additionally, Poole et al. [13] found no association between prediagnosis phobic anxiety symptoms and OC survival utilizing the Crown–Crisp phobic anxiety index based on 779 cases from the Nurses' Health Studies.

Given the current lack of prospective evidence regarding the role of prediagnosis depression and anxiety symptoms in OC survival, we analyzed data from a prospective cohort study—the Ovarian Cancer Follow-Up Study (OOPS)—conducted in Shenyang, China, to investigate this topic.

2. Methods: Study Population

The OOPS was an ongoing prospective longitudinal cohort study that started in 2015 and consecutively enrolled newly diagnosed OC patients aged 18–75 years. The patients were enrolled from the Gynecological Oncology Ward at Shengjing Hospital of China Medical University, Shenyang, China from 2015 to 2020 [14]. Briefly, 853 OC patients had been recruited and the overall study participation rate exceeded 90% ($n = 796$). For this analysis, we excluded OC patients without completed questionnaires ($n = 52$), with questionnaires containing 11 (10%) or more blank food items ($n = 24$), questionnaires lacking mentally relevant information ($n = 105$), and those with implausible caloric intakes (<500 or >3500 calories/day) ($n = 17$) [14,15]. Finally, 598 OC patients were included in the current analysis (Figure 1). The protocol for OOPS was approved by the Medical Ethics Committee of Shengjing Hospital of China Medical University. All patients provided written informed consent before participation.




Figure 1. Flow of participants through the Ovarian Cancer Follow-Up Study (OOPS) study.

At baseline, OC patients completed a detailed self-administered questionnaire of demographics and lifestyle factors, including educational level, monthly household income, physical activity, smoking status, alcohol drinking, and tea drinking [16,17]. Anthropometric measurements, including the current weight, height, and circumference of the waist and hips, were also collected by trained staff following a standard protocol [16,17]. During the in-person interview, newly diagnosed OC patients were asked about their usual frequency of consumption of each food item and sleep status, which were included in the 111-item validated food frequency and the Pittsburgh Sleep Quality Index (PSQI) questionnaire in the 12 months before diagnosis, respectively [17–19]. The PSQI consists of 19 items that could reflect on seven major sleep components, including sleep quality and sleep duration, with each component weighted on a 0–3 scale and a maximum score of 21. A total score higher than 5 indicates poor sleep quality [20].

Stressful life events refer to everyday life events, including 10 items in the past 2 years [21]. Based on the electronic medical records of the hospital information system, each OC patient was linked with her clinical information. These characteristics included age at diagnosis, histological type, histopathological grade, International Federation of Gynecology and Obstetrics (FIGO) stage, residual lesions, and comorbidities (hypertension, coronary heart disease, diabetes, and others).

Immunohistochemical (IHC) analysis was carried out to acquire specimens of OC and adjacent tissue after surgery. In brief, specimens were formalin-fixed and paraffin-embedded, then dewaxed and hydrated according to routine methods. Antigen retrieval was done using citrate buffer (pH 6.0 at 92 °C), and endogenous peroxidase activity was blocked with fresh 3% hydrogen peroxide. Afterwards, the sections were blocked with normal serum solution and incubated with a primary antibody against Wilms’s tumor 1 (WT-1), estrogen receptor (ER), progesterone receptor (PR), vimentin, and p53 (1:500, Abcam) at 4 °C overnight. The sections were subsequently incubated with corresponding secondary antibodies for 30 min at 37 °C and rinsed with phosphate-buffered saline (PBS). Finally, sections were treated with diaminobenzidine and hematoxylin for coloration and counterstaining. Staining was evaluated according to positively stained cell percentage and staining intensity. All indicators [WT-1, ER, PR, vimentin, and p53] were divided into positive and negative. IHC expression was manually confirmed by two independent experienced pathologists.

2.1. Assessment of Depression and Anxiety

Prediagnosis mental health status was assessed at recruitment with the 9-item Patient Health Questionnaire (PHQ-9) and the 7-item Generalized Anxiety Disorder (GAD-7). The PHQ-9 is a self-report questionnaire comprising nine questions and is used to calculate a depression severity score based on symptoms over a two-week period with high internal consistency, reliability, and validity [22,23]. The PHQ-9 is based on the Primary Care Evaluation of Mental Disorders (PRIME-MD) diagnostic instrument and utilizes nine DSM-IV criteria. Each of the nine items is scored from 0 (not at all) to 3 (nearly every day), giving a total score range between 0 and 27. The total score reflects depression symptom severity with a range of 0–4, 5–9, 10–14, 15–19, and ≥ 20 , indicating no, mild, moderate, moderately severe, and severe depressive symptoms, respectively [24]. In addition, patients with PHQ-9 ≥ 10 are considered to have symptomatic depression [25]. The GAD-7 is a self-administered tool for assessing generalized anxiety disorder and anxiety-related symptoms on the basis of PRIME-MD, which has good sensitivity and specificity [26,27]. Each item is scored on a scale of 0 to 3, with a total score range between 0 and 21 [28]. Total scores of 5, 10, and 15 indicate mild, moderate, and severe anxiety, respectively. The optimal cutoff score is 5 for anxiety symptoms [29].

2.2. Cohort Follow-Up and Outcome Ascertainment

The OOPS participants were followed up until mortality from any cause or the last follow-up (31 March 2021). Data on vital statistics were obtained annually by active follow-up of patients and record linkage to the Vital Statistics Unit in the Liaoning Center for Disease Control and Prevention.

3. Statistical Analysis

We compared descriptive statistics of general and clinical characteristics based on prediagnostic depression and anxiety symptoms using analysis of variance for continuous variables and the chi-square test for categorical variables. The Kaplan–Meier technique was used to plot crude survival curves and estimate the overall crude survival (OS) probabilities. Adjusted hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were derived from Cox proportional hazards regression models where the entry time was the date at which the OC patients were enrolled in the OOPS. The exit date was when the participant died or was censored due to loss to follow-up or end of study follow-up on 31 March 2021, using whichever censoring date occurred first. The proportional hazards assumption was tested by including an interaction term between depression and anxiety symptoms with the logarithm of time, and no violations were discovered (all $p > 0.05$).

The total depression and anxiety scores were dichotomized, and patients who scored above 10 and 5 were considered as having symptomatic depression and anxiety, respectively. The HR and 95% CI for each category were estimated compared to those with non-depression symptoms and non-anxiety symptoms. Models were adjusted for potential confounding factors. Model 1 included age at diagnosis (continuous, years) and body mass index (BMI) (continuous, kg/m²). Model 2 was further adjusted for dietary changes (yes or no), education (junior secondary or below, senior high school/technical secondary school, and junior college/university or above), number of menstrual years (continuous), parity (≤ 1 or ≥ 2), and physical activity (continuous, metabolic equivalents of task hours/day). Further adjustments were also made for total sleep duration (continuous, hours/day), sleep quality (good or bad, PSQI score ≤ 5 defined good, PSQI score > 5 defined bad) [19], and stressful life events in the past two years before diagnosis (yes or no) to minimize the impact of lifestyle factors and dietary factors on survival. In model 3, we further adjusted for comorbidities (yes or no), FIGO stage (I–II, III–IV, or unknown), histological type (serous or nonserous), histopathological grade (well, moderate, or poorly differentiated), and residual lesions (none, < 1 , or ≥ 1 cm). Multicollinearity among covariance was evaluated using the variance inflation factor. Moreover, we performed a further

analysis evaluating whether the severity of depression and anxiety symptoms were associated with OC survival, adjusting in the same multivariate model (model 3).

Stratified analyses were conducted for age at diagnosis (<50 vs. ≥50 years), menopausal status (no vs. yes), FIGO stage (I–II vs. III–IV), residual lesions (no vs. yes), histological type (serous vs. nonserous), BMI (<24 vs. ≥24 kg/m²), total sleep duration (<8 vs. ≥8 h/day), sleep quality (bad vs. good), and any major events (no vs. yes). We included multiple interaction terms and tested their significance using a likelihood ratio test to seek out interaction. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Two-sided *p* values less than 0.05 were considered statistically significant.

4. Results

Table 1 shows the baseline characteristics of the participants in the cohort study. During a median follow-up of 37.2 months (interquartile range 24.7–50.2 months), 130 deaths were documented due to all causes. Among all OC patients, the prevalence of depression and anxiety was 9.4% and 39.3%, respectively. OC patients with depression had a lower degree of education and higher parity. They were more likely to have shorter sleep duration and worse sleep quality, whereas patients with anxiety symptoms were more likely to be on a lower income and their sleep status was worse than non-anxiety patients. A nonserous histological subtype, later-stage disease, and more significant residual disease were statistically significantly associated with worse survival in this cohort (Supplementary Table S1).

Table 1. Baseline characteristics of ovarian cancer patients by depression and anxiety symptoms (*n* = 598).

Characteristics	All Patients	Depression Symptoms [†]		Anxiety Symptoms [†]	
		Yes	No	Yes	No
No. of patients/deaths	598/130	56/19	542/111	235/49	363/81
Mean (SD) age at diagnosis (years)	53.34 (9.45)	53.68 (7.40)	53.30 (9.64)	53.04 (9.21)	53.53 (9.61)
Mean (SD) follow-up time (months)	35.01 (16.86)	32.08 (19.19)	35.31 (16.60)	35.57 (15.01)	34.64 (17.97)
Mean (SD) body mass index (kg/m ²)	23.25 (3.55)	22.64 (3.50)	23.31 (3.55)	23.41 (3.52)	23.15 (3.57)
Mean (SD) physical activity (MET hours/day)	15.80 (11.11)	15.96 (12.54)	15.78 (10.97)	16.34 (11.43)	15.45 (10.90)
Mean (SD) sleep duration (hours) *	7.73 (1.32)	7.42 (1.47)	7.77 (1.30)	7.48 (1.30)	7.88 (1.32)
Mean (SD) sleep quality *	6.35 (3.95)	9.94 (3.96)	6.00 (3.78)	7.09 (3.98)	5.86 (3.86)
Ever cigarette smoking	64 (10.70)	3 (5.36)	61 (11.25)	26 (11.06)	38 (10.47)
Ever alcohol drinking	135 (22.58)	13 (23.21)	122 (22.51)	52 (22.13)	83 (22.87)
Ever tea drinking	195 (32.61)	15 (26.79)	180 (33.21)	73 (31.06)	122 (33.61)
Ever menopause	435 (72.74)	41 (73.21)	394 (72.69)	161 (68.51)	274 (75.48)
Experienced stressful life events in past two years	218 (36.45)	27 (48.21)	191 (35.24)	90 (38.30)	128 (35.26)
Ever dietary change before diagnosis	136 (22.74)	10 (17.86)	126 (23.25)	56 (23.83)	80 (22.04)
Parity					
≤1	421 (70.40)	37 (66.07)	384 (70.85)	162 (68.94)	259 (71.35)
≥2	177 (29.60)	19 (33.93)	158 (29.15)	73 (31.06)	104 (28.65)
Educational level					
Junior secondary or below	315 (52.68)	38 (67.86)	277 (51.11)	123 (52.34)	192 (52.89)
Senior high school/technical secondary school	125 (20.90)	9 (16.07)	116 (21.40)	47 (20.00)	78 (21.49)
Junior college/university or above	158 (26.42)	9 (16.07)	149 (27.49)	65 (27.66)	93 (25.62)
Income per month (Yuan)					
<5000	357 (59.70)	37 (66.07)	320 (59.04)	128 (54.47)	229 (63.09)
5000 to <10,000	167 (27.93)	16 (28.57)	151 (27.86)	66 (28.09)	101 (27.82)
≥10,000	74 (12.37)	3 (5.36)	71 (13.10)	41 (17.45)	33 (9.09)

Mean (SD) total energy intake (kcal/day)	1457.96 (565.15)	1390.86 (487.45)	1464.89 (572.53)	1466.96 (583.19)	1452.13 (553.90)
Mean (SD) vegetables intake (gram/day)	217.99 (123.71)	213.04 (102.80)	218.50 (125.74)	212.28 (117.05)	221.69 (127.86)
Mean (SD) fruit intake (gram/day)	197.80 (155.14)	189.50 (129.85)	198.66 (157.60)	205.68 (164.59)	192.70 (148.71)
Mean (SD) meat intake (gram/day)	36.86 (29.96)	38.42 (26.90)	36.70 (30.27)	38.89 (31.82)	35.55 (28.65)
Mean (SD) soy food intake (gram/day)	87.08 (80.63)	81.65 (65.39)	87.65 (82.08)	83.63 (78.69)	89.32 (81.90)

MET, metabolic equivalents of task; SD, standard deviation. * Sleep duration and quality was evaluated according to Pittsburgh sleep quality index. † Depression symptom was evaluated according to Patient Health Questionnaire-9 (No: score <10). ‡ Anxiety symptom was evaluated according to Generalized Anxiety Disorder-7 (No: score <5). Values are numbers (percentages) unless stated otherwise.

The association of prediagnosis depression and anxiety symptoms with OS of OC patients is shown in Figure 2, Supplementary Table S2 and Figure S1. Of these 130 deaths, 19 (14.62%) and 11 (8.46%) had depression and severe depression, while 41 (31.54%) and 8 (6.15%) had anxiety and severe anxiety, respectively. In most adjusted models, patients with depressive symptoms had a significantly increased risk of OC mortality than non-depression symptom patients (HR = 2.10, 95% CI: 1.20–3.70). Additionally, worse survival was detected for OC patients with severe depression symptoms when compared with non-depression symptom patients (HR = 2.10, 95% CI: 1.07–4.12). However, neither anxiety symptoms nor severity was associated with OC survival. Notably, OC patients with combined moderate depression and anxiety symptoms had a substantially increased risk of OC mortality (HR = 3.23, 95% CI: 1.14–9.11) compared with no depression and anxiety symptoms (Table 2).




Figure 2. Adjusted hazard ratio and 95% confidence intervals for the association between depression and anxiety symptoms and total mortality among 598 ovarian cancer patients. CI, confidence interval, Ref, reference. Depression symptom was evaluated according to Patient Health Questionnaire-9. Anxiety symptom was evaluated according to Generalized Anxiety Disorder-7.

Table 2. Adjusted hazard ratio and 95% confidence interval for the interaction between depression and anxiety symptoms and total mortality among 598 ovarian cancer patients *.

	Anxiety Symptoms			P Interaction †
	None (Score <5)	Moderate (Score 5–9)	Severe (Score ≥10)	
Depression symptoms				
None (score <10)	1.00 (Ref.)	0.64 (0.36–1.15)	2.23 (0.63–8.39)	0.26
Moderate (score 10–14)	1.32 (0.29–5.93)	3.23 (1.14–9.11)	—	
Severe (score ≥15)	2.52 (0.69–9.26)	2.28 (0.75–6.95)	1.50 (0.51–4.39)	

Ref., reference. Depression symptom was evaluated according to Patient Health Questionnaire-9. Anxiety symptom was evaluated according to Generalized Anxiety Disorder-7. * Hazard ratio and 95% confidence interval was calculated with the use of the Cox proportional hazards regression model. † Test for interaction based on depression and anxiety symptoms. Model was adjusted for age at diagnosis, body mass index, income level, dietary pattern, sleep duration and quality, dietary change, education, number of menstrual years, parity, physical activity, experience any major events in the past two years, comorbidities, FIGO stage, histological type, histopathologic grade, and residual lesions.

In subgroup analyses, significant associations between depression symptoms and OC mortality were detected in patients with age at diagnosis less than 50 years, BMI < 24 kg/m², sleep duration ≥ 8 h/day, poor sleep quality, no stressful life events, nonserous histological type, residual lesions, and patients with stage I–II (Supplementary Figure S2 and S3). Additionally, OC patients with anxiety symptoms had an increased mortality risk in the subgroup that had never experienced any stressful life events. No statistically significant interactions were observed, except for the association between depression symptoms and OC mortality stratified by age at diagnosis and histological type ($p < 0.05$). However, the subgroup analyses of immunohistochemical biomarkers showed that significant inverse associations were present in women with depression who were WT-1-negative and vimentin-negative (Supplementary Figure S4 and S5). Notably, there were significant interactions between WT-1 expression and depression and anxiety symptoms ($p < 0.05$).

5. Discussion

5.1. Main Findings

To our knowledge, this is the first prospective cohort study to investigate the relationship between prediagnosis depression and anxiety symptoms and OC survival, assessed with PHQ-9 and GAD-7, respectively. Our findings revealed that prediagnosis depression, not anxiety symptoms, was associated with decreased OC survival.

5.2. Interpretation

Although several previous studies have evaluated the association of depression and anxiety symptoms with OC risk [10], the evidence for the influence of depression and anxiety symptoms on OC survival is scarce and limited. Only one retrospective study of 642 high-grade serous OC patients suggested that depression symptoms, assessed by Elixhauser comorbidity score within the year prior to diagnosis, were inversely associated with OC survival [12]. Although we evaluated the depression symptoms of OC patients with PHQ-9 in a prospective cohort design, our results were consistent with their findings. In support of our findings, evidence from other cancers has linked depressive symptomatology with reduced cancer survival [30,31]. For example, a cohort study of 3095 breast cancer patients reported that women with newly developed depression before diagnosis had a modest but significantly increased risk of death [32]. Likewise, in a British cohort study of 2144 head and neck cancer patients, worse survival was evident among patients with pretreatment depression symptoms [33]. For anxiety symptoms, our finding is in line with a previous study of 779 OC patients in the US [13], where a nonsignificant association

between prediagnosis symptoms, evaluated by the Crown–Crisp phobic anxiety index, and OC survival was observed.

The results of several previous studies on breast cancer agree with our findings to a certain degree. These studies did not support anxiety symptoms having an important impact on breast cancer outcomes [34,35]. Nevertheless, the prevalence of prediagnosis depression and anxiety in our study is inconsistent with a previous meta-analysis [11], which might be attributed to several factors, including an inability to stratify by disease stage, the predominantly cross-sectional design of the included studies with relatively limited power, inconsistency of the depression and anxiety assessment method, and considerable differences in the prevalence estimates across the included studies owing to the high levels of heterogeneity identified for both depression and anxiety. Additionally, a population-based cohort study from Taiwan failed to identify a relationship between anxiety disorder and the risk of cancer [36].

Furthermore, several studies have shown that ER, PR, and p53 expression were the independent prognostic factors for survival in OC patients [37,38], whereas vimentin expression was positively correlated with histological grade of serous OC [39]. WT-1 was a highly sensitive and specific IHC marker for diagnosing ovarian high-grade serous carcinomas [40]. It has been indicated that serous OC patients have better survival compared with other histological types in previous studies of OOPS [17]. What is more, our findings supported the view that the association between depression and OC survival might be modified by immunohistochemical biomarkers, such as WT-1. However, as the number of patients in some categories was relatively limited, we could not rule out the possibility of chance findings, and future studies are warranted to validate these interactions.

Several underlying mechanisms may be biological in OC patients with depression. Depression may be expected to result in abnormal activation of the hypothalamic–pituitary–adrenal axis and high norepinephrine and cortisol levels, with consequent suppression of the immune response to tumors [8]. After that, long-term dysfunction of the immune system might give rise to the suppression of DNA-repair enzymes and NK cell function, leading to a worse prognosis [8,41]. Furthermore, evidence shows that depression is related to inflammatory markers such as interleukin 1,6 and C-reactive protein, which could be used as independent prognostic variables of OC [42,43]. An animal experiment has validated that chronic stress can result in higher levels of tissue catecholamines, greater tumor burden, and more invasive growth of OC [44]. Mounting evidence has highlighted the substantial genetic, neurobiological, and symptomatic overlap between depression and anxiety disorders that frequently co-occur [45–47]. Furthermore, previous evidence suggested that anxiety disorder was associated with shorter telomeres [48] and higher circulating levels of inflammatory cytokines [49], both related to OC risk and progression [50–52]. Future studies should further explore the exact and detailed biological mechanisms of depression and anxiety symptoms and their influence on the prognosis of OC.

Notably, some explanations might be related to psychological behavior changes among OC patients with depression. For example, individuals with depression may be more prone to unhealthy lifestyles, including physical inactivity, malnutrition, and insomnia, resulting in diminished quality of life and a reduction in the ability to care for oneself. [53–55]. Treatment nonadherence also might be a severe problem. There is evidence that cancer patients with depression symptom have difficulties adhering to chemotherapy and other complementary treatments, which could lead to faster cancer progression [8,56–58]. In addition, depression was highly correlated with demoralization characterized by hopelessness, helplessness, and loss of meaning and purpose, which was associated with suicidal thoughts and the desire to die [59–61]. A mediation analysis has shown that hopelessness influenced the desire for hastened death, whereas depression was a moderator in the relationship between them [62]. Moreover, depression rendered patients less capable of functioning successfully in society and diminished purpose in life, and thus could contribute to worse OC survival [63,64].

6. Strengths and Limitations

Our study has several unique strengths. Firstly, we investigated the association of prediagnosis depression and anxiety symptoms and their combined symptoms and OC survival in a prospective cohort study. Additionally, our study used the validated PHQ-9 and GAD-7 to assess depression and anxiety symptoms, respectively. Reliable related measures were obtained by trained staff and confirmation of death events through medical records and cancer registry. Besides, we validated varying information on a broad spectrum of known or plausible confounders, such as lifestyle factors, dietary habits, BMI, sleep duration and quality, and physical activity, which allowed relatively rigorous control for confounding throughout the analysis to minimize potential bias. Notably, the OOPS had excellent baseline and follow-up retention rates (92.7%). Finally, the numerous subgroup analyses that we performed generated similar results, indicating that our findings were robust.

However, several limitations of this study should be noted. Firstly, information on the dynamic duration of depression, anxiety symptoms, history of depression and anxiety, and the antidepressant used was not available. Secondly, since depression and anxiety symptoms of patients were measured within the year prior to diagnosis, we were concerned that undetected OC might cause mood swings during the data collection period. Furthermore, the prediagnosis data may not reflect postdiagnosis status. A previous study revealed that the level of depression and anxiety varies significantly between pre- and postdiagnosis [11].

Given that the mental condition of some patients will change after a cancer diagnosis, future studies are needed to investigate the relationship between postdiagnosis depression and anxiety symptoms or possible change between pre- and postdiagnosis psychiatric symptoms and OC survival. Thirdly, the relationship between depression and anxiety and mortality is very much driven by the symptom characteristics—severity, chronicity, and type [65]. In this study, severely depressed women were less likely to volunteer to participate, and the number of patients with depression and anxiety symptoms was small, meaning that there was insufficient statistical power for detailed further analyses. Moreover, all patients were recruited from a single referral hospital in northeast China, making it difficult to generalize the results. Given that differing rates of depression and anxiety have emerged between racial and ethnic groups [66,67], more oncology centers should be established in the various regions. We used all-cause mortality rather than cancer-specific mortality as an end point, which might reduce the power in our study, although the former is considered a reasonable estimate of the latter [68]. Further research should consider more outcomes. Lastly, despite comprehensively adjusting for several established or hypothesized cancer prognostic and lifestyle factors for OC, there is always the possibility that unrecognized residual confounding factors or errors may have influenced the results shown or that some findings were due to chance. Individuals with depression and anxiety might be more prone to unhealthy lifestyles, delayed cancer diagnosis, and treatment non-adherence, which could indirectly increase the risk of mortality [53,58].

In conclusion, in this prospective study, an elevated risk of OC mortality was associated with prediagnosis depression, but not anxiety symptoms. However, further large multicenter studies are warranted to validate our findings and better understand the effect of depression and anxiety symptoms on OC survival.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jcm11247394/s1>, Table S1. Selected clinical characteristics and associations with overall survival among ovarian cancer patients ($n = 598$). Table S2. Adjusted hazard ratio and 95% confidence intervals for the association between depression and anxiety symptoms and total mortality among 598 ovarian cancer patients *. Figure S1. Kaplan–Meier survival curves for depression symptom (A), anxiety symptom (B). Figure S2. Subgroup analyses of clinical characteristics for adjusted hazard ratio and 95% confidence interval for the association between depression symptom and total mortality among 598 ovarian cancer patients. Figure S3. Subgroup analyses of clinical characteristics for adjusted hazard ratio and 95% confidence interval for the

association between anxiety symptom and total mortality among 598 ovarian cancer patients. Figure S4. Subgroup analyses of immunohistochemical biomarkers for adjusted hazard ratio and 95% confidence interval for the association between depression symptom and total mortality among 598 ovarian cancer patients. Figure S5. Subgroup analyses of immunohistochemical biomarkers for adjusted hazard ratio (HR) and 95% confidence interval (CI) for the association of anxiety symptom with total mortality among ovarian cancer patients.

Author Contributions: Y.-Z.L., T.-T.G. and Q.-J.W. conceived the study; T.-T.G., Y.-H.Z., S.G. and Q.-J.W. contributed to the design; Y.-Z.L., X.Q., S.Y., Y.K., S.G. and T.-T.G. collected the data; Y.-Z.L., F.-H.L., W.-X.C., Y.-F.W., S.Y., Y.K. and Q.-J.W. cleaned the data and checked for discrepancies; Y.-Z.L., F.-H.L. and Y.-F.W. analyzed the data; Y.-Z.L., X.Q., F.-H.L., W.-X.C., Y.-F.W., N.W., Y.-H.Z., T.-T.G. and Q.-J.W. interpreted the data. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Key R&D Program of China (2022YFC2704200 to Q.-J.W.), Natural Science Foundation of China (82073647 to Q.-J.W. and 82103914 to T.-T.G.), Liaoning Revitalization Talents Program (XLYC1907102 to Q.-J.W.), Outstanding Scientific Fund of Shengjing Hospital (Q.-J.W.), Clinical Research Cultivation Project of Shengjing hospital (S.G.), the JieBangGuaShuai Project of Liaoning Province (No.2021JH1/1040050 to Y.-H.Y.), and 345 Talent Project of Shengjing Hospital of China Medical University (M0268 to Q.-J.W. and M0952 to T.-T.G.).

Institutional Review Board Statement: The OOPS was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Ethics Committee of Shengjing Hospital of China Medical University, Shenyang, China (protocol code 2015PS38K on 28 February 2015).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are available upon request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. <https://doi.org/10.3322/caac.21660>.
2. Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics, 2018. *CA Cancer J. Clin.* **2018**, *68*, 284–296. <https://doi.org/10.3322/caac.21456>.
3. Esser, P.; Mehnert-Theuerkauf, A.; Ma, M.F.; Johansen, C.; Brähler, E.; Faller, H.; Härter, M.; Koch, U.; Schulz, H.; Wegscheider, K.; et al. Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study. *Psycho-Oncology* **2020**, *29*, 1604–1612. <https://doi.org/10.1002/pon.5471>.
4. Jia, Y.; Li, F.; Liu, Y.; Zhao, J.; Leng, M.; Chen, L. Depression and cancer risk: A systematic review and meta-analysis. *Public Health* **2017**, *149*, 138–148. <https://doi.org/10.1016/j.puhe.2017.04.026>.
5. Di Giacomo, D.; Ranieri, J.; Guerra, F.; Perilli, E.; Sánchez, M.G.; Passafiume, M.; Cannita, K.; Ficorella, C. Survivorship in young women after early breast cancer: A cross-sectional study of emotional traits along 3-years perspective. *Riv. Psichiatr.* **2019**, *54*, 160–167.
6. Machado, M.O.; Veronese, N.; Sanches, M.; Stubbs, B.; Koyanagi, A.; Thompson, T.; Tzoulaki, I.; Solmi, M.; Vancampfort, D.; Schuch, F.B.; et al. The association of depression and all-cause and cause-specific mortality: An umbrella review of systematic reviews and meta-analyses. *BMC Med.* **2018**, *16*, 1–13. <https://doi.org/10.1186/s12916-018-1101-z>.
7. Guidi, J.; Lucente, M.; Sonino, N.; Fava, G.A. Allostatic Load and Its Impact on Health: A Systematic Review. *Psychother. Psychosom.* **2020**, *90*, 11–27. <https://doi.org/10.1159/000510696>.
8. Spiegel, D.; Giese-Davis, J. Depression and cancer: Mechanisms and disease progression. *Biol. Psychiatry* **2003**, *54*, 269–282. [https://doi.org/10.1016/s0006-3223\(03\)00566-3](https://doi.org/10.1016/s0006-3223(03)00566-3).
9. Hamilton, A.B. Psychological aspects of ovarian cancer. *Cancer Investig.* **1999**, *17*, 335–341. <https://doi.org/10.3109/07357909909032875>.
10. Wang, Y.-H.; Li, J.-Q.; Shi, J.-F.; Que, J.-Y.; Liu, J.-J.; Lappin, J.; Leung, J.; Ravindran, A.V.; Chen, W.-Q.; Qiao, Y.-L.; et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. *Mol. Psychiatry* **2019**, *25*, 1487–1499. <https://doi.org/10.1038/s41380-019-0595-x>.
11. Watts, S.; Prescott, P.; Mason, J.; McLeod, N.; Lewith, G. Depression and anxiety in ovarian cancer: A systematic review and meta-analysis of prevalence rates. *BMJ Open* **2015**, *5*, e007618. <https://doi.org/10.1136/bmjopen-2015-007618>.
12. Clarke, C.L.; Kushi, L.H.; Chubak, J.; Pawloski, P.A.; Bulkley, J.E.; Epstein, M.M.; Burnett-Hartman, A.N.; Powell, B.; Pearce, C.L.; Feigelson, H.S. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. *Cancer Epidemiol. Biomark. Prev.* **2019**, *28*, 996–999. <https://doi.org/10.1158/1055-9965.epi-18-1324>.

13. Poole, E.M.; Kubzansky, L.D.; Sood, A.K.; Okereke, O.I.; Tworoger, S.S. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. *Cancer Causes Control* **2016**, *27*, 661–668. <https://doi.org/10.1007/s10552-016-0739-0>.
14. Gong, T.-T.; Liu, F.-H.; Liu, Y.-S.; Yan, S.; Xu, H.-L.; He, X.-H.; Wei, Y.-F.; Qin, X.; Gao, S.; Zhao, Y.-H.; et al. A Follow-Up Study of Ovarian Cancer (OOPS): A Study Protocol. *Front. Nutr.* **2022**, *9*, e872773. <https://doi.org/10.3389/fnut.2022.872773>.
15. Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic studies. *Am. J. Clin. Nutr.* **1997**, *65* (Suppl. S4), 1220S–1228S. <https://doi.org/10.1093/ajcn/65.4.1220s>.
16. Jiang, L.; Gong, T.-T.; Gao, S.; Li, X.-Q.; Liu, F.-H.; Wen, Z.-Y.; Wei, Y.-F.; Yan, S.; Hou, R.; Wu, Q.-J. Pre-diagnosis Dairy Product Intake and Ovarian Cancer Mortality: Results from the Ovarian Cancer Follow-Up Study (OOPS). *Front. Nutr.* **2021**, *8*, e750801. <https://doi.org/10.3389/fnut.2021.750801>.
17. Wei, Y.-F.; Hao, Y.-Y.; Gao, S.; Li, X.-Q.; Liu, F.-H.; Wen, Z.-Y.; Wang, H.-Y.; Zhang, S.; Yan, S.; Luan, M.; et al. Pre-diagnosis Cruciferous Vegetables and Isothiocyanates Intake and Ovarian Cancer Survival: A Prospective Cohort Study. *Front. Nutr.* **2021**, *8*, e778031. <https://doi.org/10.3389/fnut.2021.778031>.
18. Gu, Y.; Zhang, S.; Wang, J.; Chi, V.T.Q.; Zhang, Q.; Liu, L.; Meng, G.; Yao, Z.; Wu, H.; Bao, X.; et al. Relationship between consumption of raw garlic and handgrip strength in a large-scale adult population. *Clin. Nutr.* **2020**, *39*, 1234–1241. <https://doi.org/10.1016/j.clnu.2019.05.015>.
19. Mollayeva, T.; Thurairajah, P.; Burton, K.; Mollayeva, S.; Shapiro, C.M.; Colantonio, A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. *Sleep Med. Rev.* **2016**, *25*, 52–73. <https://doi.org/10.1016/j.smrv.2015.01.009>.
20. Buysse, D.J.; Reynolds, C.F., 3rd; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Res.* **1989**, *28*, 193–213.
21. Chair, S.Y.; Choi, K.C.; Cao, X.; Cheng, H.Y.; Chau, J.P.C.; Liu, T.; Chien, W.T. Association between household solid fuel use for cooking and sleep disturbance in rural China: Findings from the China Kadoorie Biobank data. *Sleep Med.* **2021**, *83*, 13–20. <https://doi.org/10.1016/j.sleep.2021.04.029>.
22. He, C.; Levis, B.; Riehm, K.E.; Saadat, N.; Levis, A.W.; Azar, M.; Rice, D.B.; Krishnan, A.; Wu, Y.; Sun, Y.; et al. The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. *Psychother. Psychosom.* **2019**, *89*, 25–37. <https://doi.org/10.1159/000502294>.
23. Levis, B.; Benedetti, A.; Thombs, B.D. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: Individual participant data meta-analysis. *BMJ* **2019**, *365*, l1476. <https://doi.org/10.1136/bmj.l1476>.
24. Zimmerman, M. Using the 9-Item Patient Health Questionnaire to Screen for and Monitor Depression. *JAMA* **2019**, *322*, 2125. <https://doi.org/10.1001/jama.2019.15883>.
25. Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. *J. Gen. Intern. Med.* **2001**, *16*, 606–613.
26. Hinz, A.; Klein, A.M.; Brähler, E.; Glaesmer, H.; Luck, T.; Riedel-Heller, S.G.; Wirkner, K.; Hilbert, A. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. *J. Affect. Disord.* **2017**, *210*, 338–344. <https://doi.org/10.1016/j.jad.2016.12.012>.
27. Krahe, T.; Götz, R.; Lackner, K.; Haustein, J.; Klemen, U.; Landwehr, P.; Heidebreder, E.; Schuhmann-Giampieri, G. Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis. *Rofo* **1992**, *156*, 523–526.
28. Esser, P.; Hartung, T.J.; Friedrich, M.; Johansen, C.; Wittchen, H.-U.; Faller, H.; Koch, U.; Härter, M.; Keller, M.; Schulz, H.; et al. The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients. *Psycho-Oncology* **2018**, *27*, 1509–1516. <https://doi.org/10.1002/pon.4681>.
29. Ilie, G.; Rutledge, R.; Sweeney, E. Anxiety and depression symptoms in adult males in Atlantic Canada with or without a life-time history of prostate cancer. *Psycho-Oncology* **2019**, *29*, 280–286. <https://doi.org/10.1002/pon.5244>.
30. Reháč, J. Dynamics of vascular changes in neovascular glaucoma. II. Unusual findings after cryosurgery. *Ceskoslovenska Oftalmol.* **1992**, *48*, 364–369.
31. Akechi, T.; Okamura, H.; Okuyama, T.; Furukawa, T.A.; Nishiwaki, Y.; Uchitomi, Y. Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. *Psycho-Oncology* **2008**, *18*, 23–29. <https://doi.org/10.1002/pon.1364>.
32. Liang, X.; Margolis, K.L.; Hendryx, M.; Reeves, K.; Wassertheil-Smoller, S.; Weitlauf, J.; Danhauer, S.C.; Chlebowski, R.T.; Caan, B.; Qi, L.; et al. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. *Cancer* **2017**, *123*, 3107–3115. <https://doi.org/10.1002/cncr.30688>.
33. Jansen, F.; Leeuw, I.V.-D.; Cuijpers, P.; Leemans, C.R.; Waterboer, T.; Pawlita, M.; Penfold, C.; Thomas, S.J.; Waylen, A.; Ness, A. Depressive symptoms in relation to overall survival in people with head and neck cancer: A longitudinal cohort study. *Psycho-Oncology* **2018**, *27*, 2245–2256. <https://doi.org/10.1002/pon.4816>.
34. Iglay, K.; Santorelli, M.L.; Hirshfield, K.M.; Williams, J.M.; Rhoads, G.G.; Lin, Y.; Demissie, K. Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients with Breast Cancer. *J. Clin. Oncol.* **2017**, *35*, 4012–4018. <https://doi.org/10.1200/jco.2017.73.4947>.
35. A Moustsen, P.; Vinter, N.; Aas-Andersen, L.; Kragstrup, J. Laser treatment of sinusitis in general practice assessed by a double-blind controlled study. *Ugeskrift for Læger* **1991**, *153*, 2232–4.
36. Liang, J.A.; Sun, L.M.; Su, K.P.; Chang, S.N.; Sung, F.C.; Muo, C.H.; Kao, C.H. nationwide population-based cohort study: Will anxiety disorders increase subsequent cancer risk? *PLoS ONE* **2012**, *7*, e36370.

37. Malamou-Mitsi, V.; Crikoni, O.; Timotheadou, E.; Aravantinos, G.; Vrettou, E.; Agnantis, N.; Fountzilas, G. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. *Anticancer Res.* **2007**, *27*, 1157–1165.
38. Sieh, W.; Köbel, M.; A Longacre, T.; Bowtell, D.D.; Defazio, A.; Goodman, M.T.; Høgdall, E.; Deen, S.; Wentzensen, N.; Moysich, K.B.; et al. Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncol.* **2013**, *14*, 853–862. [https://doi.org/10.1016/s1470-2045\(13\)70253-5](https://doi.org/10.1016/s1470-2045(13)70253-5).
39. Goel, A.; Rao, N.M.; Santhi, V.; Byna, S.S.; Grandhi, B.; Conjeevaram, J. Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to Cytokeratin and Vimentin. *Iran. J. Pathol.* **2018**, *13*, 23–29. <https://doi.org/10.30699/ijp.13.1.23>.
40. Rekhi, B.; Deodhar, K.K.; Menon, S.; Maheshwari, A.; Bajpai, J.; Ghosh, J.; Shylasree, S.T.; Gupta, S. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. *APMIS* **2017**, *126*, 45–55. <https://doi.org/10.1111/apm.12784>.
41. Baltrusch, H.J.; Stangel, W.; Titze, I. Stress, cancer and immunity. New developments in biopsychosocial and psychoneuroimmunologic research. *Acta Neurol.* **1991**, *13*, 315–327.
42. Brummett, B.H.; Boyle, S.H.; Ortel, T.L.; Becker, R.C.; Siegler, I.C.; Williams, R.B. Associations of Depressive Symptoms, Trait Hostility, and Gender with C-Reactive Protein and Interleukin-6 Response After Emotion Recall. *Psychosom. Med.* **2010**, *72*, 333–339. <https://doi.org/10.1097/psy.0b013e3181d2f104>.
43. Hefler, L.A.; Concin, N.; Hofstetter, G.; Marth, C.; Mustea, A.; Sehoul, J.; Zeillinger, R.; Leipold, H.; Lass, H.; Grimm, C.; et al. Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer. *Clin. Cancer Res.* **2008**, *14*, 710–714. <https://doi.org/10.1158/1078-0432.ccr-07-1044>.
44. Thaker, P.H.; Han, L.Y.; A Kamat, A.; Arevalo, J.M.; Takahashi, R.; Lu, C.; Jennings, N.B.; Armaiz-Pena, G.N.; Bankson, J.; Ravoori, M.; et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat. Med.* **2006**, *12*, 939–944. <https://doi.org/10.1038/nm1447>.
45. Pizzagalli, D.A. Psychobiology of the intersection and divergence of depression and anxiety. *Depression Anxiety* **2016**, *33*, 891–894. <https://doi.org/10.1002/da.22550>.
46. Arden-Close, E.; Gidron, Y.; Moss-Morris, R. Psychological distress and its correlates in ovarian cancer: A systematic review. *Psycho-Oncology* **2008**, *17*, 1061–1072. <https://doi.org/10.1002/pon.1363>.
47. Hipkins, J.; Whitworth, M.; Tarrier, N.; Jayson, G. Social support, anxiety and depression after chemotherapy for ovarian cancer: A prospective study. *Br. J. Health Psychol.* **2004**, *9*, 569–581. <https://doi.org/10.1348/1359107042304542>.
48. Okereke, O.I.; Prescott, J.; Wong, J.Y.Y.; Han, J.; Rexrode, K.M.; De Vivo, I. High Phobic Anxiety Is Related to Lower Leukocyte Telomere Length in Women. *PLoS ONE* **2012**, *7*, e40516. <https://doi.org/10.1371/journal.pone.0040516>.
49. Brennan, A.M.; Fargnoli, J.L.; Williams, C.J.; Li, T.; Willett, W.; Kawachi, I.; Qi, L.; Hu, F.B.; Mantzoros, C.S. Phobic Anxiety Is Associated with Higher Serum Concentrations of Adipokines and Cytokines in Women with Diabetes. *Diabetes Care* **2009**, *32*, 926–931. <https://doi.org/10.2337/dc08-1979>.
50. Delgado, B.M.; Yanowsky, K.; Inglada, L.; de la Hoya, M.; Caldes, T.; Vega, A.; Blanco, A.; Martin, T.; Gonzalez-Sarmiento, R.; Blasco, M.A.; et al. Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. *J. Med. Genet.* **2012**, *49*, 341–344. <https://doi.org/10.1136/jmedgenet-2012-100807>.
51. Nogue, S.; Pou, R.; Fernandez, J.; Sanz-Gallen, P. Fatal hydrogen sulphide poisoning in unconfined spaces. *Occup. Med.* **2011**, *61*, 212–214. <https://doi.org/10.1093/occmed/kqr021>.
52. Toriola, A.T.; Grankvist, K.; Agborsangaya, C.B.; Lukanova, A.; Lehtinen, M.; Surcel, H.-M. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: A longitudinal study. *Ann. Oncol.* **2011**, *22*, 1916–1921. <https://doi.org/10.1093/annonc/mdq694>.
53. Strine, T.W.; Mokdad, A.H.; Dube, S.R.; Balluz, L.S.; Gonzalez, O.; Berry, J.T.; Manderscheid, R.; Kroenke, K. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. *Gen. Hosp. Psychiatry* **2008**, *30*, 127–137. <https://doi.org/10.1016/j.genhosppsych.2007.12.008>.
54. Koenig, H.G.; Cohen, H.J.; Blazer, D.G.; Meador, K.G.; Westlund, R. A Brief Depression Scale for Use in the Medically Ill. *Int. J. Psychiatry Med.* **1992**, *22*, 183–195. <https://doi.org/10.2190/m1f5-f40p-c4kd-ypa3>.
55. Pelletier, G.; Verhoef, M.J.; Khatri, N.; Hagen, N. Quality of Life in Brain Tumor Patients: The Relative Contributions of Depression, Fatigue, Emotional Distress, and Existential Issues. *J. Neuro-Oncology* **2002**, *57*, 41–49. <https://doi.org/10.1023/a:1015728825642>.
56. Smith, S.; Sestak, I.; Forster, A.; Partridge, A.; Side, L.; Wolf, M.; Horne, R.; Wardle, J.; Cuzick, J. Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. *Ann. Oncol.* **2016**, *27*, 575–590. <https://doi.org/10.1093/annonc/mdv590>.
57. Crawshaw, J.; Auyeung, V.; Norton, S.; Weinman, J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. *J. Psychosom. Res.* **2016**, *90*, 10–32. <https://doi.org/10.1016/j.jpsychores.2016.09.003>.
58. Kisely, S.; Crowe, E.; Lawrence, D. Cancer-Related Mortality in People with Mental Illness. *JAMA Psychiatry* **2013**, *70*, 209–217. <https://doi.org/10.1001/jamapsychiatry.2013.278>.
59. Tang, L.; Li, Z.; Pang, Y. The differences and the relationship between demoralization and depression in Chinese cancer patients. *Psycho-Oncology* **2019**, *29*, 532–538. <https://doi.org/10.1002/pon.5296>.

60. Kissane, D.W.; Wein, S.; Love, A.; Lee, X.Q.; Kee, P.L.; Clarke, D.M. The Demoralization Scale: A Report of its Development and Preliminary Validation. *J. Palliat. Care* **2004**, *20*, 269–276. <https://doi.org/10.1177/082585970402000402>.
61. Lee, C.-Y.; Fang, C.-K.; Yang, Y.-C.; Liu, C.-L.; Leu, Y.-S.; Wang, T.-E.; Chang, Y.-F.; Hsieh, R.-K.; Chen, Y.-J.; Tsai, L.-Y.; et al. Demoralization syndrome among cancer outpatients in Taiwan. *Support. Care Cancer* **2011**, *20*, 2259–2267. <https://doi.org/10.1007/s00520-011-1332-4>.
62. Parpa, E.; Tsilika, E.; Galanos, A.; Nikoloudi, M.; Mystakidou, K. Depression as mediator and or moderator on the relationship between hopelessness and patients' desire for hastened death. *Support. Care Cancer* **2019**, *27*, 4353–4358. <https://doi.org/10.1007/s00520-019-04715-2>.
63. Hedberg, P.; Gustafson, Y.; Al  x, L.; Brulin, C. Depression in relation to purpose in life among a very old population: A five-year follow-up study. *Aging Ment. Health* **2010**, *14*, 757–763. <https://doi.org/10.1080/13607861003713216>.
64. Boyes, A.W.; Girgis, A.; Zucca, A.C.; Lecathelinais, C. Anxiety and depression among long-term survivors of cancer in Australia: Results of a population-based survey. *Med. J. Aust.* **2009**, *190*, S94–S98.
65. Jamison, R.N.; Burish, T.G.; A Wallston, K. Psychogenic factors in predicting survival of breast cancer patients. *J. Clin. Oncol.* **1987**, *5*, 768–772. <https://doi.org/10.1200/jco.1987.5.5.768>.
66. Luckett, T.; Goldstein, D.; Butow, P.N.; Gebiski, V.; Aldridge, L.J.; McGrane, J.; Ng, W.; King, M.T. Psychological morbidity and quality of life of ethnic minority patients with cancer: A systematic review and meta-analysis. *Lancet Oncol.* **2011**, *12*, 1240–1248. [https://doi.org/10.1016/s1470-2045\(11\)70212-1](https://doi.org/10.1016/s1470-2045(11)70212-1).
67. Huang, Y.; Wang, Y.; Wang, H.; Liu, Z.; Yu, X.; Yan, J.; Yu, Y.; Kou, C.; Xu, X.; Lu, J.; et al. Prevalence of mental disorders in China: A cross-sectional epidemiological study. *Lancet Psychiatry* **2019**, *6*, 211–224. [https://doi.org/10.1016/s2215-0366\(18\)30511-x](https://doi.org/10.1016/s2215-0366(18)30511-x).
68. Brewer, K.C.; Peterson, C.E.; Davis, F.G.; Hoskins, K.; Pauls, H.; Joslin, C.E. The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: A population-based analysis of Cook County, Illinois. *Ann. Epidemiol.* **2015**, *25*, 556–563. <https://doi.org/10.1016/j.annepidem.2015.03.021>.